Front Page News
Community Spotlight: Laura Watson
Laura Watson is team captain of Laura’s Dream Team and fundraising committee co-chair of the North New Jersey Cure SMA Chapter. On Saturday, June 22, […]
Read More ›The 2019 Annual SMA Conference Booklet is Now Posted Online
The 2019 Annual SMA Conference booklet is now available for download. The booklet includes information on workshops, special events and details of the Annual SMA […]
Read More ›Family Friendly Research Poster Session Presenters Announced
The Family Friendly Research Poster Session will be held on Saturday, June 29th from 6:30pm to 8:00pm at the 2019 Annual SMA Conference. The Family […]
Read More ›Biogen Issues Q2 Community Statement on Spinraza
Dear members of the SMA community, We are grateful for the opportunity to continue to help support individuals with spinal muscular atrophy (SMA), their caregivers […]
Read More ›Team Cure SMA Celebrates Global Running Day!
Happy Global Running Day! Is Global Running Day a made-up holiday? Kind of. But unlike other made-up holidays dedicated to eating pancakes or taking selfies, […]
Read More ›Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
Scholar Rock today announced positive final top-line results from the Phase 1 clinical trial of its product candidate, SRK-015, a highly specific inhibitor of myostatin […]
Read More ›Cure SMA to Host “Evening in the Park” at Disneyland Thanks to Support from AveXis
Conference attendees will enjoy a magical “Evening in the Park” at Disneyland thanks to special support from AveXis, a Novartis company. All registered attendees for […]
Read More ›AveXis and Cure SMA to Co-Host Webinar on the FDA’s Approval of Zolgensma
On Wednesday, June 12th, at 10am CDT (8am PDT/9am MDT/11am EDT) AveXis, a Novartis company, and Cure SMA will co-host a webinar on the FDA […]
Read More ›AveXis Issues Community Statement on Zolgensma Approval
Dear SMA Community, We have exciting news to share with you — a major milestone has been reached in the fight against spinal muscular atrophy […]
Read More ›AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age
AveXis, Inc., a Novartis company, today announced that they have received FDA approval for Zolgensma (formerly AVXS-101), a gene therapy that replaces the survival motor […]
Read More ›